GILD vs TAK
Gilead Sciences vs Takeda Pharmaceutical Company Limited — AI-powered side-by-side comparison
GILD
Gilead Sciences
51
Watch
VS
TAK
Takeda Pharmaceutical Company Limited
63
Buy
| Metric | GILD | TAK |
|---|
| AI Score |
51
|
63
|
| Price |
$148.12
|
$18.25
|
| P/E Ratio |
-57.22×
|
51.30×
|
| ROE |
37.5%
|
2.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
79.6%
|
62.1%
|
| Debt / Equity |
2.22×
|
0.65×
|
| Dividend Yield |
2.2%
|
3.4%
|
| RSI (14) |
76.0
|
70.6
|
| Beta |
0.336
|
0.088
|
| Expected Upside |
+5.7%
|
+2.5%
|
AI Committee View
Current Innellis committee reasoning for GILD versus TAK.
TAK leads by 12 points.
TAK scores 63/100 (Buy) versus GILD at 51/100 (Watch).
GILD Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case. Value Analyst remains cautious — price-to-book of 6.7x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Dividend yield of 4.0% pays you to wait — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Price-to-book of 6.7x prices in significant intangible value — Value
- ROE of only -16.3% -- cheap may mean cheap for a reason — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
TAK Committee View
60% agreement
5 analysts
Positive signals support the current rating — price structure making higher highs and higher lows. The committee sees sufficient evidence to maintain the constructive view.
Bull Case
- Price-to-book of 1.2x is a discount to asset value — Value
- Dividend yield of 4.4% pays you to wait — Value
- 3 consecutive earnings beats -- consistent execution — Growth
Bear Case
- ROE of only -2.2% -- cheap may mean cheap for a reason — Value